HCV elimination in a Swiss opioid agonist therapy programme – a cohort study
BACKGROUND: In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic direct-acting antivirals irrespective of live...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2022-12-01
|
| Series: | Swiss Medical Weekly |
| Online Access: | https://smw.ch/index.php/smw/article/view/3257 |
| _version_ | 1811288885116796928 |
|---|---|
| author | Andrea Bregenzer Cornelia Krismer Stefanie Wendel Patrik Roser Christoph A. Fux |
| author_facet | Andrea Bregenzer Cornelia Krismer Stefanie Wendel Patrik Roser Christoph A. Fux |
| author_sort | Andrea Bregenzer |
| collection | DOAJ |
| description |
BACKGROUND: In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic direct-acting antivirals irrespective of liver fibrosis stage. Until the end of 2021, however, prescription was restricted to infectious disease specialists, gastroenterologists and certain addiction specialists. Difficult venous access after long-term intravenous drug use and, in the case of referral to a specialist, difficulties keeping appointments are barriers to HCV diagnosis and treatment.
AIMS: To assess whether minimally invasive point-of-care tests and a “test-and-treat / vaccinate on-site” approach can improve human immunodeficiency virus (HIV) / hepatitis C virus (HCV) screening, HCV treatment uptake and immunity against hepatitis A/B.
METHODS: Since September 2018, an infectious disease specialist and a study nurse performed 4-weekly visits in the OAT programme “HAG” (heroin dispensation of the canton Aargau), offering HIV/HCV antibody rapid testing (20 min) and HCV RNA quantification (GeneXpert®, 60 min) from capillary blood, noninvasive liver fibrosis assessment (Fibroscan®, 5–10 min) and HCV treatment prescription on-site. Recommended venous blood draws for HAV/HBV serology and HAV/HBV vaccinations were performed by the staff of the “HAG”. Project performance was assessed by annual cross-sectional chart review.
RESULTS: Of the 128 patients registered in April 2018, 79 (62%) were still present in May 2021. With 72 newly registered, a total of 200 patients could be assessed, of whom 129 (65%) were still present in May 2021. Between April 2018 and May 2021, the proportion ever tested for HIV antibodies increased from 79% (101/128) to 91% (117/129), the proportion ever tested for HCV antibodies from 83% (106/128) to 93% (120/129) and the proportion of those HCV antibody positive ever tested for HCV RNA tested from 89% (47/53) to 98% (56/57). The proportion with adequate HCV management (last HCV antibody test ≤1 year ago, if HCV antibody negative or last HCV RNA test ≤1 year ago, if HCV antibody-positive and RNA-negative) improved from 23% ([15 + 15]/128) to 80% ([55 + 48]/129). Overall, HCV treatment uptake increased from 60% (21/35) to 92% (55/60) and HCV RNA prevalence among the HCV antibody positives decreased from 38% (18/47) to 7% (6/84). Between 2018 and 2021, 19 non-cirrhotic chronic hepatitis C patients were successfully treated on-site (18 sustained virological responses [SVR] 12, 1 SVR4), with excellent adherence (≥93%) and, so far, no reinfection. The proportion with known HAV/HBV serostatus increased from 38%/51% to 64%/76%. Immunity against HAV/HBV improved from 19%/23% to 50%/57%.
CONCLUSION: Capillary blood point-of-care tests and a “test-and-treat / vaccinate on-site” approach remove crucial barriers to diagnosis and treatment, making hepatitis elimination in OAT programmes achievable. A high fluctuation rate requires HIV/HCV/HAV/HBV testing at admission, but also allows more patients to be screened.
|
| first_indexed | 2024-04-13T03:44:08Z |
| format | Article |
| id | doaj.art-f2932f8e22914e6eb34c5c73bfac927d |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-13T03:44:08Z |
| publishDate | 2022-12-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-f2932f8e22914e6eb34c5c73bfac927d2022-12-22T03:04:03ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972022-12-01152495010.57187/smw.2022.40009HCV elimination in a Swiss opioid agonist therapy programme – a cohort studyAndrea BregenzerCornelia KrismerStefanie WendelPatrik RoserChristoph A. Fux BACKGROUND: In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic direct-acting antivirals irrespective of liver fibrosis stage. Until the end of 2021, however, prescription was restricted to infectious disease specialists, gastroenterologists and certain addiction specialists. Difficult venous access after long-term intravenous drug use and, in the case of referral to a specialist, difficulties keeping appointments are barriers to HCV diagnosis and treatment. AIMS: To assess whether minimally invasive point-of-care tests and a “test-and-treat / vaccinate on-site” approach can improve human immunodeficiency virus (HIV) / hepatitis C virus (HCV) screening, HCV treatment uptake and immunity against hepatitis A/B. METHODS: Since September 2018, an infectious disease specialist and a study nurse performed 4-weekly visits in the OAT programme “HAG” (heroin dispensation of the canton Aargau), offering HIV/HCV antibody rapid testing (20 min) and HCV RNA quantification (GeneXpert®, 60 min) from capillary blood, noninvasive liver fibrosis assessment (Fibroscan®, 5–10 min) and HCV treatment prescription on-site. Recommended venous blood draws for HAV/HBV serology and HAV/HBV vaccinations were performed by the staff of the “HAG”. Project performance was assessed by annual cross-sectional chart review. RESULTS: Of the 128 patients registered in April 2018, 79 (62%) were still present in May 2021. With 72 newly registered, a total of 200 patients could be assessed, of whom 129 (65%) were still present in May 2021. Between April 2018 and May 2021, the proportion ever tested for HIV antibodies increased from 79% (101/128) to 91% (117/129), the proportion ever tested for HCV antibodies from 83% (106/128) to 93% (120/129) and the proportion of those HCV antibody positive ever tested for HCV RNA tested from 89% (47/53) to 98% (56/57). The proportion with adequate HCV management (last HCV antibody test ≤1 year ago, if HCV antibody negative or last HCV RNA test ≤1 year ago, if HCV antibody-positive and RNA-negative) improved from 23% ([15 + 15]/128) to 80% ([55 + 48]/129). Overall, HCV treatment uptake increased from 60% (21/35) to 92% (55/60) and HCV RNA prevalence among the HCV antibody positives decreased from 38% (18/47) to 7% (6/84). Between 2018 and 2021, 19 non-cirrhotic chronic hepatitis C patients were successfully treated on-site (18 sustained virological responses [SVR] 12, 1 SVR4), with excellent adherence (≥93%) and, so far, no reinfection. The proportion with known HAV/HBV serostatus increased from 38%/51% to 64%/76%. Immunity against HAV/HBV improved from 19%/23% to 50%/57%. CONCLUSION: Capillary blood point-of-care tests and a “test-and-treat / vaccinate on-site” approach remove crucial barriers to diagnosis and treatment, making hepatitis elimination in OAT programmes achievable. A high fluctuation rate requires HIV/HCV/HAV/HBV testing at admission, but also allows more patients to be screened. https://smw.ch/index.php/smw/article/view/3257 |
| spellingShingle | Andrea Bregenzer Cornelia Krismer Stefanie Wendel Patrik Roser Christoph A. Fux HCV elimination in a Swiss opioid agonist therapy programme – a cohort study Swiss Medical Weekly |
| title | HCV elimination in a Swiss opioid agonist therapy programme – a cohort study |
| title_full | HCV elimination in a Swiss opioid agonist therapy programme – a cohort study |
| title_fullStr | HCV elimination in a Swiss opioid agonist therapy programme – a cohort study |
| title_full_unstemmed | HCV elimination in a Swiss opioid agonist therapy programme – a cohort study |
| title_short | HCV elimination in a Swiss opioid agonist therapy programme – a cohort study |
| title_sort | hcv elimination in a swiss opioid agonist therapy programme a cohort study |
| url | https://smw.ch/index.php/smw/article/view/3257 |
| work_keys_str_mv | AT andreabregenzer hcveliminationinaswissopioidagonisttherapyprogrammeacohortstudy AT corneliakrismer hcveliminationinaswissopioidagonisttherapyprogrammeacohortstudy AT stefaniewendel hcveliminationinaswissopioidagonisttherapyprogrammeacohortstudy AT patrikroser hcveliminationinaswissopioidagonisttherapyprogrammeacohortstudy AT christophafux hcveliminationinaswissopioidagonisttherapyprogrammeacohortstudy |